davelizomib   Click here for help

GtoPdb Ligand ID: 12887

Compound class: Synthetic organic
Comment: The structure for davelizomib was obtained from proposed INN list 129 (August 2023) where it is described as a proteasome inhibitor and antineoplastic agent. It is example I-1 in patent JP2021531302A. This patent encompasses use of claimed compounds for the treatment of multiple myeloma, and identifies its potential in MM that is resistant to treatment with the existing proteasome inhibitor bortezomib.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 3
Rotatable bonds 12
Topological polar surface area 134.27
Molecular weight 481.26
XLogP 1.52
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)C[C@@H](B1O[C@@H](CC(=O)O)C(=O)O1)NC(=O)CNC(=O)[C@@H]2CCN2C3=CC=C(C=C3F)F
Isomeric SMILES B1(O[C@H](C(=O)O1)CC(=O)O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H]2CCN2C3=C(C=C(C=C3)F)F
InChI InChI=1S/C21H26BF2N3O7/c1-11(2)7-17(22-33-16(9-19(29)30)21(32)34-22)26-18(28)10-25-20(31)15-5-6-27(15)14-4-3-12(23)8-13(14)24/h3-4,8,11,15-17H,5-7,9-10H2,1-2H3,(H,25,31)(H,26,28)(H,29,30)/t15-,16-,17-/m0/s1
InChI Key BMSAGHWUHGTMIV-ULQDDVLXSA-N
Bioactivity Comments
Davelizomib (I-1) inhibits proliferation of MM cells with an IC50 of 13 nM in vitro [1].